Amgen Invests $30M In Immatics, Up To $1 Billion In Future Payments
socalTECH
JANUARY 9, 2017
Thousand Oaks-based Amgen announced this morning that it has made a $30M investment in a German company developing cancer immunotherapy, Immatics Biotechnologies GmbH. The two said that Amgen will be responsible for the clinical development, manufacturing and commercialization worldwide of the new drugs.
Let's personalize your content